Management of Warfarin-Associated Intracranial Hemorrhage
Initial Treatment and Reversal Strategies
- The American Heart Association recommends immediate discontinuation of warfarin upon diagnosis of intracranial hemorrhage (ICH) 4
- Administer 4-factor PCC (such as Octaplex) as soon as possible, without waiting for INR results, with dosing based on INR and body weight (25-50 IU/kg) 4, 5
- For INR ≥2.0, use standard dosing protocol, and for INR <2.0 but ≥1.3, consider lower dose of 10-20 IU/kg 5
- Always administer intravenous vitamin K (5-10 mg) alongside PCC to prevent rebound increases in INR, targeting INR correction to <1.5 1, 2, 5
Safety and Efficacy Considerations
- Higher doses of PCC (>2000-3000 IU) may increase risk of venous thromboembolism, and consider patient's underlying thrombotic risk factors before administration 5
- Avoid recombinant activated factor VII (rFVIIa) as first-line therapy due to increased thromboembolic risk, especially in elderly patients 3
Clinical Outcomes and Anticoagulation Resumption
- Rapid INR correction with PCC is associated with reduced hematoma expansion, and early administration (within 4 hours) combined with blood pressure control is associated with lower in-hospital mortality 4, 5
- The decision to restart anticoagulation should balance thromboembolic risk against risk of recurrent hemorrhage, and limited data suggest that reinstitution of warfarin after 7-10 days may be safe in selected patients 6, 7